Evaluating Innovations in Middle Molecule Clearance

Dr Jeff Giullian speaks At the 2026 Renal Physicians Association Meeting. He is standing at a podium with a black backdrop.

“The secret of the care of the patient is in caring for the patient.”¹

None of us would ever choose to have kidney failure. And that is exactly why innovations that help patients feel better and live healthier are critical to our work serving the kidney community.  

Middle molecule clearance is emerging as a meaningful therapeutic target in kidney care, with important implications for inflammation, cardiovascular risk, and perhaps most importantly, recovery after dialysis.

With middle molecule clearance as a benchmark, DaVita is exploring two pathways to address: hemodiafiltration and expanded hemodialysis using high‑performance membrane dialyzers, both of which show promise in international clinical research. At the same time, defining a new standard of care requires validating these therapies in the U.S. to understand their impact on… READ MORE ON LINKEDIN